Phase 3
Completed N=72
Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Source: ClinicalTrials.gov NCT01661790 ↗Enrolled (actual)
72
Serious AEs
0.0%
Results posted
Mar 2015
Primary outcomePrimary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
Summary
To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With "Complete Response" and "Partial Response" |
17; 2; 13; 15 | — |
| SECONDARY Median Progression Free Survival (PFS) |
— | — |
| SECONDARY Overall Survival (OS) |
— | — |
| SECONDARY Adverse Reactions |
— | — |
| SECONDARY Qualify of Life (QoL) |
— | — |
Eligibility Criteria
Inclusion Criteria
- Patients with advanced recurrent or progressive NSCLC proven cytohistologically
- Karnofsky performance status (KPS) ≥60
- Life expectancy ≥ 2 months
- No history of severe diseases of major organs including liver, heart, and kidney
- No previous intrapleural therapy
- Written informed consent
Exclusion Criteria
- Active thoracic cavity or systemic bleeding
- Active pleural or systemic infection.
- Known sensitivity to Bevacizumab or Cisplatin
- Refusal to participate in the study.
Data sourced from ClinicalTrials.gov (NCT01661790). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.